疾病治疗 > 药物治疗 > 介绍性文章

    维A酸类药物在皮肤科应用临床进展2013.11.21
    近年发现,维甲酸受体属于皮质类固醇-甲状腺-维生素D3受体族,有维甲酸受体(RARs)和维甲酸X受体(RXRs),且均有α、β和γ三种亚型。维甲酸在表皮和毛囊中主要是通过RAR-γ和RXR-α这两种受体亚型产生活性的,能直接调节基因转录,参与并调节细胞...

    脱敏治疗2013.11.21
    提到脱敏治疗首先我们应该了解什么是过敏反应,过敏的一般概念是什么? 过敏的英文翻译是“hypersensitive”或者“hypersensitivity”,一个是名词形式,一个是形容词形式; Hypersensitive:Extremely sensitive to any change in conditions,to ...

    糖皮质激素在皮肤科的应用2013.11.21
    一 糖皮质激素在皮肤科应用历史 从最初认识肾上腺到大量肾上腺糖皮质激素类药物的发明和使用,经历了几百年的漫长历史。 1563年,意大利医生首次注意到肾上腺的存在; 1935年,Kendall首先描述由动物肾上腺皮质提取的粗制皮质激素,就是E合剂,主要...

    几种老药在皮肤科的临床应用2013.11.21
    应用于痤疮的治疗:痤疮杆菌在痤疮的发病中起重要作用,实验表明二甲胺四环素抑制5种生物型痤疮丙酸杆菌株培养液中的中性粒细胞趋化因子,可以使丙酸杆菌减少的数量较四环素多10倍,美满霉素50mg口服,一日两次分别于四环素、红霉素、甲硝唑进行临床...

    抗组胺药物在皮肤科的应用2013.11.21
    组胺是一种结构简单的重要自体活性物质,在体内有组氨酸脱羧基形成,主要以无活性的结合型存在于肥大细胞核嗜碱性粒细胞的颗粒中,组织损伤、炎症、神经刺激、过敏反应可引起这些细胞脱颗粒,导致组胺(游离型)释放,与组胺受体结合而产生生物效应...

    Vitiligo Treatment with Monochromatic Excimer Light and Tacrolimus: Results of an Open Randomized Co...2013.11.20
    BACKGROUND DATA: Narrow band ultraviolet B (UVB) is an effective and safe option for the treatment of vitiligo. However, a complete and long-lasting repigmention of vitiligo patches is difficult to achieve. Combined treatments w...

    Clinical efficacy of a novel topical formulation for vitiligo: compared evaluation of different trea...2013.11.20
    Abstract Current vitiligo treatmentsare not always satisfactory for both patients and dermatologists.Recently, combination therapies have been introduced in order to obtain betterresults and reduce risks in the management of the d...

    Easy ways to improve your care2013.11.20
    AbstractFor patients of any age, facial lesions can cause considerable embarrassment and distress. Read on to discover what key component of acnetreatment you should be using (but probably aren't) and which dosage you can safe...

    阿维A酸治疗脓疱性银屑病及红皮病2013.11.20
    我科2002年4月-2003年1月采用阿维A酸(商品名:新体卡松,上海罗氏制药有限公司)治疗脓疱性银屑病和(或)红皮病性银屑病、毛发红糠疹继发的红皮病,取得了一定的疗效,现将我们治疗的8例患者临床疗效观察结果总结如下.

    Treatment of Severe Psoriasis with Infliximab: Report of Two Cases2013.11.20
    Abstract Infliximab is an anti-tumornecrosis factor-monoclonal antibody shown to be effective in the treatment of moderate-to-severe psoriasis and psoriatic arthritis. We report on the first two patients inCroatiain which the effi...
共有10条记录  当前第1页  首页 上一页 下一页 尾页